English
Home > Products > CAS NO 2018-66-8

China CAS NO 2018-66-8 Factory

The shopper satisfaction is our primary focus on. We uphold a consistent level of professionalism, quality, credibility and repair for CAS NO 2018-66-8,2018-66-8,N-Cbz-L-Leucine, With the advancement of society and economy, our enterprise will continue to keep a tenet of "Focus on trust, high quality the first", moreover, we expect to produce a wonderful future with each customer.
CAS NO 2018-66-8, Our Company has specialist engineers and technical staff to answer your questions about maintenance problems, some common failure. Our product quality assurance, price concessions, any questions about the products, You should feel free to contact us.

Related Products

Hot Products

  • 1-Boc-3-Azetidinone

    1-Boc-3-Azetidinone

    Product Name:1-Boc-3-azetidinone
    Molecular Formula:C8H13NO3
    Molecular Weight:171.19
    CAS Registry Number:398489-26-4
  • Remdesivir

    Remdesivir

    Product Name:Remdesivir
    Molecular Formula:C27H35N6O8P
    Molecular Weight;602.58
    CAS Registry Number;1809249-37-3
  • 1-[2-Chloro-1-hydroxy-3-(6-quinolinyl)propyl]-2,5-pyrrolidinedione

    1-[2-Chloro-1-hydroxy-3-(6-quinolinyl)propyl]-2,5-pyrrolidinedione

    Product Name:1-[2-Chloro-1-hydroxy-3-(6-quinolinyl)propyl]-2,5-pyrrolidinedione
    Molecular Formula:C16H15ClN2O3
    Molecular Weight:318.75
    CAS Registry Number:1197377-31-3
  • L-Threonic acid magnesium salt

    L-Threonic acid magnesium salt

    Product Name:L-Threonic acid magnesium salt
    Molecular Formula:C8H14MgO10
    Molecular Weight:294.5
    CAS Registry Number:778571-57-6
  • Tolterodine tartrate

    Tolterodine tartrate

    Product Name:Tolterodine tartrate
    Molecular Formula:C26H37NO7
    Molecular Weight;475.57
    CAS Registry Number;124937-52-6
  • 4-((6,7-Dimethoxyquinolin-4-yl)oxy)aniline

    4-((6,7-Dimethoxyquinolin-4-yl)oxy)aniline

    Product Name:4-((6,7-Dimethoxyquinolin-4-yl)oxy)aniline
    Molecular Formula:C17H16N2O3
    Molecular Weight:296.32
    CAS Registry Number:190728-25-7
  • Related Blog
  • Reviews

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • Caffeine CAS No.58-08-2

    Caffeine (CAS No.58-08-2) is a xanthine alkaloid compound, a central nervous stimulant that temporarily drives away drowsiness and restores energy, and is used clinically to treat neurosis and coma recovery. Caffeinated coffee, tea, soft drinks and energy drinks are very popular, so caffeine is also the most commonly used psychotropic drug in the world.

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications.

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept